BETHANAMIST

Bethanamist is focused on developing revolutionary cures for swallowing disorders caused by Ineffective Esophageal Motility (IEM). The Company's primary patent protected formulation has been shown to be highly effective in treating swallowing difficulties (Dysphagia), which can frequently result from stroke, ALS, Alzheimer's, Parkinson's, cancers and other diseases. Bethanamist is in the process of initiating FDA approved Phase II clinical trials.